BioWorld MedTech

Nov. 18, 2016

Disappointed Endologix stumbles as FDA calls for more Nellix EVAS system data

A "disappointed" Endologix Inc. (Nasdaq:ELGX) now is anticipating a second quarter 2018 approval of the Nellix endovascular aneurysm sealing (EVAS) system following the FDA's request for two-year patient follow-up data. Read More

FDA relaxes imaging protocol mandates in 510(k) final for MR

China med tech a hot sector for M&A thanks to regulatory reforms

Limflow wins CE mark for device sparing lower limbs for No-Option patients

What's next now that the JOBS Act is fully implemented?

Financings

Product briefs

Appointments and advancements

MDD's Diagnostics Extra

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...